SCHEMBL6513744

SCHEMBL6513744

CCOC=Cc1c(C(N)=O)ncc2c1cc(O)n2Cc1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
KDM4E B2RXH2 3/20 0.40
PKM P14618 1/20 0.40
GRIN1 Q05586 7/20 0.39
GRIN2B Q13224 7/20 0.39
HTT P42858 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
TP53 P04637 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495861 0.75 PDE4B (0.39) MAPTKDM4EPKMHTTALDH1A1
SCHEMBL3495858 0.75 PDE4B (0.39) MAPTKDM4EPKMHTTALDH1A1
SCHEMBL3495324 0.75 MAOB (0.38) MAPTKDM4EGRIN1GRIN2BALDH1A1
SCHEMBL3495326 0.75 MAOB (0.38) MAPTKDM4EGRIN1GRIN2BALDH1A1
SCHEMBL6513737 0.73 GAA (0.35) MAPTALDH1A1TP53EGLN1L3MBTL1
SCHEMBL3495549 0.72 HDAC6 (0.43) GRIN1GRIN2BEGLN1L3MBTL1
SCHEMBL3495556 0.72 HDAC6 (0.43) GRIN1GRIN2BEGLN1L3MBTL1
SCHEMBL27718721 0.67 THRB (0.40) MAPTALDH1A1POLBTP53L3MBTL1
SCHEMBL4975644 0.67 MMP1 (0.36) MAPTKDM4EALDH1A1TP53L3MBTL1
SCHEMBL4975638 0.67 MMP1 (0.36) MAPTKDM4EALDH1A1TP53L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050277661-A1 Inhibitors of the HIV integrase enzyme AGOURON PHARMACEUTICALS, INC. 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277661-A1 Inhibitors of the HIV integrase enzyme IMPDH1, INTS9, TYMP MAPT 600/4885KDM4E 821/4885PKM 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.